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TRIAL INFORMATION
• ClinicalTrials.gov Identifier: NCT02191878
• Sponsor(s): Arbutus Biopharma, Inc.
• Principal Investigator: Ghassan K. Abou-Alfa
• IRB Approved: Yes
LESSONS LEARNED
• TKM-080301 showed a favorable toxicity profile at the studied dose.
• TKM-080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in
patients with advanced hepatocellular carcinoma compared with historical control. Preliminary antitumor activity as
shown in this early-phase study does not support further evaluation as a single agent.
ABSTRACT
Background. Polo-like kinase 1 (PLK1) is overexpressed in
hepatocellular carcinoma (HCC). Knockdown of PLK1
expression by PLK1 small interfering RNA (siRNA) in an HCC
cell line showed reduced expression in RNA-induced silenc-
ing complex and a reduction in cell proliferation.
Methods. A 3 + 3 dose escalation plus expansion cohort at
the maximum tolerated dose (MTD) was implemented.
Patients with HCC, Eastern Cooperative Oncology Group
(ECOG) performance status ≤2, and Child-Pugh score A
received TKM-080301 as an intravenous infusion once every
week for 3 consecutive weeks, repeated every 28 days.
Results. The study enrolled 43 patients. The starting
dose of TKM-080301 was 0.3 mg/kg, and MTD was de-
clared at 0.75 mg/kg. Following the development of grade
4 thrombocytopenia in two subjects on the expansion cohort,
the MTD was redefined at 0.6 mg/kg. Four patients did not
have any evaluable postbaseline scan. Of the other 39 subjects
who had received at least 0.3 mg/kg, 18 subjects (46.2%) had
stable disease (SD) by independent RECIST 1.1 criteria. By Choi
criteria, eight subjects (23.1%) had a partial response (PR). For
37 assessable subjects, with 2 subjects censored, median
progression-free survival (PFS) was 2.04 months. Median sur-
vival for the whole study population was 7.5 months.
Conclusion. TKM-080301 was generally well tolerated.
In this early-phase study, antitumor effect for TKM 080301
was limited. Further evaluation as a single agent in
large randomized trials is not warranted. The Oncologist
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Clinical Trial Results
DISCUSSION
PLK1 is a validated molecular target in oncology [1] and
has been shown to play nonredundant roles in cell cycle
regulation [2]. Expression of PLK1 in HCC tumor samples
from 56 patients with HCC was shown to be up to 12-fold
higher than in controls, and its overexpression is a negative
prognostic indicator of patients’ outcomes. Inhibition of
PLK1 activity in proliferating cancer cells rapidly induces
mitotic arrest and apoptosis [3] and can sensitize cancer
cells to cytotoxic effects of chemotherapy [4]. TKM-080301
evaluation in patients with HCC was limited by the devel-
opment of thrombocytopenia in two subjects dosed at
0.75 mg/kg in the initial expansion cohort; thus, the recom-
mended dose was reduced to 0.6 mg/kg. Other than tran-
sient delayed infusion reactions that responded to
standard therapy, TKM-080301 was well tolerated. No
deaths were related to TKM-080301.
We analyzed responses based on the Choi criteria,
given that it may be more appropriate than RECIST 1.1 to
identify responders in advanced HCC [5], and we observed
23.1% PRs (waterfall plot available online), whereas RECIST
1.1 showed no PR or complete response.
An exploratory assessment of overall survival (OS) was
performed, revealing a median OS of 7.5 months (Fig. 1).
This compares favorably with the median OS of 6.5 months
reported for subjects treated with sorafenib in a phase III
study in the Asia-Pacific region with similar subject demo-
graphics to the current study [6], and with placebo arms in
second-line studies. In summary, TKM-080301 was gener-
ally well tolerated by most subjects, but with modest anti-
tumor activity and insufficient data to support further
exploration.
TRIAL INFORMATION
Disease Hepatocellular carcinoma
Stage of Disease / Treatment Metastatic / advanced
Prior Therapy No designated number of regimens
Type of Study – 1 Phase I
Type of Study – 2 3 + 3
Primary Endpoint Safety
Primary Endpoint Tolerability
Primary Endpoint Pharmacokinetics
Secondary Endpoint Efficacy
Investigator’s Analysis Drug tolerable, efficacy indeterminant
DRUG INFORMATION
Drug 1
Generic/Working Name New drug
Trade Name TKM-080301
Company Name Arbutus Biopharma, Inc.
Drug Type Biological
Drug Class siRNA
Dose 0.3 milligrams (mg) per kilogram (kg)
Route Intravenous
Schedule of Administration Once every week for 3 consecutive weeks, repeated every
28 days
Figure 1. Waterfall plot on percentage change from baseline in
target tumor diameter. Best response (RECIST) was assessed
by central imaging (intent-to-treat population).
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DOSE ESCALATION TABLE
Dose level Dose of drug: new drug, mg/kg Number enrolled Number evaluable for toxicity
1 0.3 3 3
2 0.6 9 9
3 0.75 15 15
Added to 0.6 at MTD 0.6 16 16
PATIENT CHARACTERISTICS
Number of Patients, Male 36
Number of Patients, Female 7
Stage IV
Age Median (range): 62 years
Number of Prior Systemic Therapies Median (range): 1
Performance Status: ECOG 0 — 23
1 — 20
2 —
3 —
Unknown —
Cancer Types or Histologic Subtypes Hepatocellular carcinoma, 43
PRIMARY ASSESSMENT METHOD
Title Response assessment by RECIST
Number of Patients Screened 43
Number of Patients Enrolled 43
Number of Patients Evaluable for Toxicity 43
Number of Patients Evaluated for Efficacy 39
Response Assessment – PR n = 1
Response Assessment – SD n = 20
Response Assessment – PD n = 18
(Median) Duration Assessments – PFS 2 months
(Median) Duration Assessments – OS 8 months
Waterfall plot on percentage change from baseline in target
tumor diameter. Best response (RECIST) was assessed by cen-
tral imaging (intent-to-treat population).
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RESPONSE ASSESSMENT BY CHOI CRITERIA
Response Assessment – PR n = 17
Response Assessment – SD n = 6
Response Assessment – PD n = 14
Response Assessment – Other n = 2
SERIOUS ADVERSE EVENTS
Name Grade Attribution
Leucocytosis 3 Probable
Thrombocytopenia 4 Probable
Cardiac disorder not otherwise defined 3 Probable
Abdominal pain 3 Possible
Ascites 3 Probable
Gastric ulcer hemorrhage 4 Probable
Peritoneal hemorrhage 4 Probable
Pyrexia 3 Probable
Noncardiac chest pain 3 Possible
Hepatic failure 3 Possible
Cholangitis 4 Possible
Infections 3 Probable
Sepsis 4 Probable
Infusion-related reaction 3 Definite
Hypercalcemia 3 Probable
Musculoskeletal pain 3 Possible
Tumor hemorrhage 4 Possible
Acute kidney injury 3 Possible
Pulmonary embolism 3 Probable
Deep vein thrombosis 3 Probable
Hypotension 3 Probable
Waterfall plot on percentage change from baseline in target tumor density (Choi).
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DOSE-LIMITING TOXICITIES
Dose level
Number
enrolled
Number evaluable for
toxicity
Number with a dose-
limiting toxicity
Dose-limiting toxicity
information
0.3 3 3
0.6 9 9 1 Grade 1 chills
0.75 15 15 4 Grade 2 chills,
thrombocytopenia
Added to 0.6
MTD
16 16
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study completed
Investigator’s Assessment Drug tolerable, efficacy indeterminant
Knockdown of polo-like kinase 1 (PLK1) expression by
PLK1 small interfering RNA (siRNA) in hepatocellular carci-
noma (HCC) cell lines showed a reduction in PLK1 protein
expression of 96% and up to 92% reduction in a multiprotein
complex, specifically a ribonucleoprotein, which incorporates
one strand of a single-stranded RNA fragment, such as
microRNA, or double-stranded siRNA, also called RNA-
induced silencing complex [7]. PLK1 overexpression has
also been associated with metastatic disease [8] and poor
prognosis in HCC. Studies with TKM-080301 in preclinical
models of human cancer have demonstrated that TKM-
080301 has robust anticancer activity in both subcutaneous
and orthotopic liver tumor models in mice [9]. TKM-080301
is a lipid nanoparticle (LNP) formulation comprising four
lipids and a synthetic, double-stranded siRNA directed
against human PLK1 mRNA. Synthetic siRNAs are a duplex
of complementary RNA oligonucleotides designed to
achieve post-transcriptional gene suppression through the
RNA interference mechanism [10].
TKM-080301 was designed for systemic intravenous
delivery of siRNA to solid tumors and has been prepared in
the form of LNPs, which can accumulate within tumors tak-
ing advantage of the “enhanced permeation and retention”
effect [11, 12]. The lipid components of TKM-080301 also
protect the siRNA from degradation by plasma and tissue
nucleases, prevent rapid clearance of the siRNA, and
enable effective intracellular uptake of the PLK1-targeting
siRNA into cancer cells [13].
Pharmacology studies evaluating single- and multiple-
dose pharmacodynamic evaluations of TKM-080301 in vari-
ous subcutaneous tumor models and in an orthotopic
mouse model of human liver cancer have demonstrated
human PLK1 mRNA silencing, significant survival benefit,
and significant tumor growth inhibition in orthotopic mouse
models and various subcutaneous models of human cancer.
Liver is the primary tissue of distribution of TKM-
080301, along with spleen, and to a lesser extent the adre-
nals. Approximately 66%–83% and 1.5%–3.2% of a total
injected dose of TKM-080301 accumulates in the liver and
spleen of mice, respectively.
This was a multicenter, open-label, nonrandomized, dose
escalation phase I/II study conducted at 15 sites in six coun-
tries (the U.S., Canada, Hong Kong, the Republic of Korea,
Singapore, and Taiwan). The study was designed to deter-
mine the safety, tolerability, pharmacokinetics, and antitu-
mor activity of TKM-080301 in adult subjects with
metastatic or locally advanced inoperable HCC that is refrac-
tory to, or unsuitable for standard therapy. A conservative
starting dose of 0.3 mg/kg was selected for this study to
establish the safety of TKM-080301 in subjects with locally
advanced or metastatic HCC. The study was restricted to
patients with HCC with preserved hepatic function classified
as Child-Pugh A. Subsequent dose escalations to 0.6 mg/kg
and 0.75 mg/kg were planned. The maximum planned dose
in this study was 0.75 mg/kg. Treatment cycles consisted of
a single intravenous infusion of TKM-080301 over 60 minutes
once weekly for 3 consecutive weeks, followed by a rest
week, repeated every 4 weeks. To minimize the risk of
infusion-related reactions, all subjects received a steroid pro-
phylaxis regimen prior to each dose of TKM-080301, which
was reduced according to a prescribed schedule if TKM-
080301 was well tolerated.
Subjects who demonstrated clinical benefit without
progression might have continued up to six complete
cycles and might have received treatment beyond six cycles
with the approval of the sponsor’s medical monitor if the
investigator considered it in the best interests of the sub-
ject. Subjects would then have continued TKM-080301
therapy until withdrawal of consent, disease progression,
or unacceptable toxicity occurred.
The study was divided into two phases. The dose esca-
lation phase was to enroll three cohorts of three to six sub-
jects each, with each cohort assigned to receive successive
increases of a predefined TKM-080301 dose escalation
based on prior clinical experience with TKM-80301 in
advanced solid tumors.
The starting dose of TKM-080301 was 0.3 mg/kg per
dose (Cohort 1), and sequential cohorts were to receive
TKM-080301 0.6 mg/kg per dose (Cohort 2) and
0.75 mg/kg per dose (Cohort 3), provided that dose-
limiting toxicities (DLTs) were seen in none or no more
than one subject during the preceding cycle. Once the
maximum tolerated dose (MTD) had been established,
ongoing subjects receiving a dose lower than the MTD
might have had their dose increased to the MTD or an
intermediate dose level if in the opinion of the
© AlphaMed Press 2018www.TheOncologist.com
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investigator and sponsor the subject may receive addi-
tional clinical benefit. Dose escalation proceeded without
incident for Cohort 2 (0.6 mg/kg) and Cohort
3 (0.75 mg/kg). Safety was assessed during each cycle,
including liver function tests and electrocardiograms. The
potential for immune-related toxicities and infusion reac-
tions were investigated during the first dose of cycle
1. Serial pharmacokinetic sampling was taken for cycle
1, doses 1 and 2, and for cycle 2, dose 1. A preinfusion
sample was collected prior to dose 1 in each subsequent
cycle. DLTs were defined as grade 4 toxicity considered
possibly, probably, or definitely related to TKM 080301.
Assessment for preliminary evidence of antitumor activity
(response rate according to RECIST 1.1 criteria) was a sec-
ondary objective of the study. Overall tumor response was
assessed at the end of cycle 2 and every two cycles thereaf-
ter, and/or upon study discontinuation by the investigator.
Clinical benefit rate was assessed in the expansion cohort
and was defined as the sum of all subjects with RECIST 1.1
defined complete response (CR), partial response (PR), minor
response (MR; ≥20% decrease of target tumors but <30%
decrease), stable disease (SD) lasting ≥16 weeks, and ≥ 50%
decrease in alpha-fetoprotein (AFP) from baseline.
A total of 12 subjects (three subjects at 0.3 mg/kg, five
subjects at 0.6 mg/kg, and four subjects at 0.75 mg/kg)
had been dosed. Two subjects in the 0.3 mg/kg group
remained on therapy. No DLTs were observed in Cohort
1 (0.3 mg/kg) or Cohort 2 (0.6 mg/kg). Review of subse-
quent adverse events (AEs) for subjects in those groups
revealed that approximately 90% of the reported AEs were
mild to moderate in severity, and most AEs were assessed
to be unrelated or unlikely related to study drug by the
investigator. A total of six subjects reported a total of
11 serious AEs (SAEs), but none of the SAEs was assessed
as serious, unexpected, and treatment related. With no
DLTs noted in Cohort 3, 0.75 mg/kg was declared as the
MTD by the Safety Review Panel (SRP). The SRP also
approved the opening of the phase II expansion cohort at
the MTD of 0.75 mg/kg per week. After the development
of grade 4 thrombocytopenia in two subjects, a recom-
mended dose reduction to 0.6 mg/kg followed. The dose
reduction was applicable for all subjects on study and any
new subjects enrolled.
A total of 43 subjects were enrolled in the study at dif-
ferent dose levels: 3 subjects in the 0.3 mg/kg group, 9 sub-
jects in the 0.6 mg/kg group, 15 subjects in the 0.75 mg/kg
group, and 16 subjects in the reduction from 0.75 to
0.6 mg/kg group. All 43 subjects (100.0%) were included in
the intention-to-treat (ITT) and per protocol analysis sets.
Overall, 36 subjects (83.7%) were male and seven subjects
(16.3%) were female. The race of most subjects was Asian
(27 subjects; 62.8%) or white (14 subjects; 32.6%), and the
ethnicity of most subjects was “not Hispanic or Latino”
(38 subjects; 88.4%). The mean (range) age was 62 years
(39–79). Body mass index ranged between 18.05 and
36.32 kg/cm2. Overall, the different dose levels were gener-
ally similar regarding demographic characteristics. Life
expectancy was more than 3 months for all 43 subjects
(100%). No subjects had a New York Heart Association clas-
sification of grade II or greater. A total of 25 subjects
(58.1%) were at risk for hepatitis B, 6 subjects (14.0%)
were at risk for hepatitis C, and 9 subjects (20.9%) had no
risk factors. Most of the subjects (31 subjects; 72.1%) were
classified at the C stage in the Barcelona Clinic Liver Cancer
classification, with eight subjects (18.6%) classified at the B
stage. The Eastern Cooperative Oncology Group perfor-
mance status at screening for the overall population was
0 for 23 subjects (53.5%) and 1 for 20 subjects (46.5%).
A total of 39 subjects (90.7%) of the 43 enrolled subjects
had an evaluable postbaseline scan. Overall, as assessed by
the investigator, in subjects who received at least 0.3 mg/kg,
20 subjects (50.0%) had stable disease. Overall, as assessed
by the central imaging center, in subjects who received at
least 0.3 mg/kg, 18 subjects (46.2%) had stable disease and
20 subjects (51.3%) had progressive disease.
No subjects at any dose level met RECIST 1.1 criteria
for CR, PR, or MR. Five subjects (11.6%) overall met RECIST
1.1 criteria for SD lasting ≥16 weeks. Three subjects (7.0%)
demonstrated ≥50% decrease in AFP from baseline. Over-
all, for eight subjects (18.6%) with a clinical benefit, the
benefit was statistically significant (p = .0012). A total of
37 (86.0%) events were assessed. Six subjects (14.0%) were
censored. The median progression-free survival was
2.04 months overall with a range of 0.0 to 13.3 months
(95% confidence interval, 1.61; 3.42). Overall, 22 subjects
(51.2%) in the ITT population died, and 21 subjects (48.8%)
were censored at last contact. Three subjects’ deaths during
study treatment were reported as treatment-emergent AEs.
The median follow-up time was 7.66 months. The median
survival was 7.52 months. Overall as assessed by the investi-
gator, in subjects who received at least 0.3 mg/kg, 20
subjects (50.0%) had stable disease. As assessed by Choi
criteria, in subjects who received at least 0.3 mg/kg, 9
subjects (23.1%) had PR; 9 subjects (23.1%) of the 43 sub-
jects assessed had SD. The mean duration of best response
as assessed by Choi criteria was 18.7  35.56 days for target
response.
Treatment with TKM-080301 was generally safe and
well tolerated in subjects with HCC during this study. A
total of 41 of the 43 subjects (95.3%) of the ITT population
experienced at least one AE. A reduction in spleen volume
was observed in three subjects and was likely due to an
on-target siRNA effect of PLK1 inhibition. In these subjects,
the decline in splenic volume was not associated with clini-
cally significant functional hyposplenism. TEAEs reported in
more than one subject were pyrexia (20 subjects; 46.5%);
fatigue (16 subjects; 37.2%); chills (15 subjects; 34.9%);
peripheral edema (8 subjects; 18.6%); noncardiac chest
pain (3 subjects; 7.0%); and malaise, edema, and pain in
two subjects (4.7%) each. A total of 17 subjects (39.5%)
had at least one infusion-related TEAE. No SAE of TKM-
080301-related hepatic disease was noted. No fatal TEAE
was assessed as being possibly, probably, or definitely
related to TKM-080301. Overall, 22 subjects died (including
censoring at last contact). Three of these subjects who died
during the course of study treatment were reported as
TEAEs. All three fatal TEAES were assessed as unlikely or
not related to TKM-080301.
In conclusion, TKM-080301 was safe and well tolerated in
this population of patients with advanced HCC and adequate
© AlphaMed Press 2018
Phase I of TKM-080301 in HCCe217
liver function. Single-agent TKM-080301 did not demonstrate
clinically meaningful antitumor activity, the secondary end-
point of this trial. Any further studies of this drug in HCC
should be designed within the context of these results.
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